108 job losses, but firm sees profits rise £10m

MAJOR employer Fujifilm Diosynth Biotechnologies saw profits rise following a year in which a major restructure led to more than 100 job losses.

- COREENA FORD

The company, part of the Fujifilm Biotechnologies Group and with sites at Billingham, Darlington and Wilton in the UK, is involved in the bio-pharmaceuticals sector and works with firms across the globe in Asia, North America and Europe.

The vaccines specialist helps to meet demand by contract developing and manufacturing proteins, vaccines and antibodies, among other large molecules, for biotechnology and pharmaceutical companies who are developing new biologic medicines.

The timescale between start of clinical trials and commercialisation is typically between six and eight years, so the company says building high quality long-term relationships is fundamental to the business.

Now the firm has published accounts for the year ended March 2025, in which it highlights the major global restructure.